Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes

• Jackson K. Mukonzo ,

  * E-mail: mukojack@yahoo.co.uk

  Affiliations Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda, CIHR, Canadian HIV Trials Network, Vancouver, British Columbia, Canada

  ⨯
• Joel S. Owen,

  Affiliation School of Pharmacy, Union University, Jackson, Tennessee, United States of America

  ⨯
• Jasper Ogwal-Okeng,

  Affiliation Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda

  ⨯
• Ronald B. Kuteesa,

  Affiliation Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda

  ⨯
• Sarah Nanzigu,

  Affiliation Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda

  ⨯
• Nelson Sewankambo,

  Affiliation Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda

  ⨯
• Lehana Thabane,

  Affiliations Departments of Clinical Epidemiology and Biostatistics, Pediatrics and Anaesthesia, McMaster University, Hamilton, Ontario, Canada, Biostatistics Unit, St. Joseph’s Healthcare—Hamilton, Hamilton, Ontario, Canada

  ⨯
• Lars L. Gustafsson,

  Affiliation Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital-Huddinge, Karolinska Institutet, Stockholm, Sweden

  ⨯
• Colin Ross,

  Affiliation Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada

  ⨯
• Eleni Aklillu

  Affiliation Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital-Huddinge, Karolinska Institutet, Stockholm, Sweden

  ⨯